Limited-Stage Hodgkin Lymphoma Minimizing Toxicity

被引:2
|
作者
Straus, David J. [1 ,2 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Med, Div Hematol Oncol, Lymphoma Serv, 1275 York Ave,Box 330, New York, NY 10065 USA
[2] Weill Cornell Med, New York, NY USA
关键词
chemotherapy; combined modality; early-stage classic Hodgkin lymphoma; long-term toxicity; radiation; RADIATION-THERAPY; HEART-DISEASE; HD15; TRIAL; OPEN-LABEL; CHEMOTHERAPY; RADIOTHERAPY; RISK; ABVD; DACARBAZINE; TOMOGRAPHY;
D O I
10.1097/PPO.0000000000000329
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Early-stage classic Hodgkin lymphoma has been highly curable using extended-field radiation therapy (RT) alone, combined-modality therapy consisting of chemotherapy and RT, and more recently chemotherapy alone. Radiation therapy either to an extended field (extended-field RT) or to various iterations of an involved field (involved-field RT) is potentially associated with late morbidity and mortality, particularly second primary cancers and cardiovascular complications. Treatment with chemotherapy alone, when possible, can achieve a high cure rate while avoiding these risks. This review describes the evolution of treatment for early-stage classic Hodgkin lymphoma.
引用
收藏
页码:223 / 229
页数:7
相关论文
共 50 条
  • [31] Is Limited-Stage Mantle Cell Lymphoma Curable and How Is It Best Managed?
    Romancik, Jason T.
    Cohen, Jonathon B.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2020, 34 (05) : 849 - 859
  • [32] Progress in the Management of Limited-Stage Small Cell Lung Cancer
    Amini, Arya
    Byers, Lauren A.
    Welsh, James W.
    Komaki, Ritsuko U.
    CANCER, 2014, 120 (06) : 790 - 798
  • [33] Clinical impact of induction treatment modalities and optimal timing of radiotherapy for the treatment of limited-stage NK/T cell lymphoma
    Moon, Joon-Ho
    Lee, Bo-Hee
    Kim, Jeong-A
    Lee, Yoo Jin
    Chae, Yee Soo
    Yhim, Ho-Young
    Kwak, Jae-Yong
    Do, Young Rok
    Park, Yong
    Song, Moo-Kon
    Shin, Ho-Jin
    Kim, Therasa
    Lee, Je-jung
    Yang, Deok-Hwan
    LEUKEMIA RESEARCH, 2016, 49 : 80 - 87
  • [34] Treatment of early stage favorable and unfavorable Hodgkin lymphoma
    Sasse, S.
    Momotow, J.
    Broeckelmann, P. J.
    Baues, C.
    Eich, H. T.
    Engert, A.
    ONKOLOGIE, 2022, 28 (10): : 879 - 888
  • [35] Radioimmunotherapy in limited-stage diffuse large B-cell lymphoma
    Miao, Yi
    Fan, Lei
    Li, Jianyong
    TRANSLATIONAL CANCER RESEARCH, 2016, 5 (01) : 83 - 84
  • [36] Advanced-stage Hodgkin lymphoma
    Ferdinandus, J.
    Oertel, M.
    Eichenauer, D. A.
    Meissner, J.
    Engert, A.
    Borchmann, P.
    ONKOLOGIE, 2022, 28 (10): : 889 - 900
  • [37] Hodgkin lymphoma: Introduction
    Engert, Andreas
    Vassilakopoulos, Theodoros P.
    SEMINARS IN HEMATOLOGY, 2016, 53 (03) : 137 - 138
  • [38] Treating early-stage Hodgkin lymphoma in resource-limited settings: InPOG-HL-15-01 experience
    Mahajan, Amita
    Singh, Manisha
    Bakhshi, Sameer
    Jain, Sandeep
    Radhakrishnan, Venkatraman
    Verma, Nishant
    Seth, Rachna
    Arora, Ramandeep Singh
    Dinand, Veronique
    Kalra, Manas
    Mandal, Piali
    Kapoor, Gauri
    Sajid, Mohammad
    Thulkar, Sanjay
    Arora, Ashima
    Taluja, Ankit
    Chandra, Jagdish
    PEDIATRIC BLOOD & CANCER, 2021, 68 (10)
  • [39] Vital organ sparing with proton therapy for pediatric Hodgkin lymphoma: Toxicity and outcomes in 50 patients
    Tringale, Kathryn R.
    Modlin, Leslie A.
    Sine, Kevin
    Forlenza, Christopher J.
    Cahlon, Oren
    Wolden, Suzanne L.
    RADIOTHERAPY AND ONCOLOGY, 2022, 168 : 46 - 52
  • [40] Relapse in patients with limited-stage ocular adnexal lymphoma treated by chemoimmunotherapy: Extended follow-up of a phase 2 study
    Kim, Sung-Yong
    Lee, Won-Sik
    Oh, Sung Yong
    Yang, Deok-Hwan
    Kim, Hyo Jung
    Park, Seong Kyu
    Yang, Jae Wook
    Yang, Suk-Woo
    Cho, Seok-Goo
    CANCER MEDICINE, 2022, 11 (14): : 2817 - 2823